Los Angeles, United States
Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company, is making waves in the healthcare landscape through its pioneering efforts in real-world AI eye screening. Founded in 2010 and headquartered in the United States, Eyenuk stands out as the leader in autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and monitoring.
The company’s flagship product, the EyeArt AI Eye Screening System, sets the benchmark as the most validated AI technology for diabetic retinopathy detection. Eyenuk’s mission is ambitious yet critical: to screen every eye globally for early diagnosis of significant health threats like diabetic retinopathy, glaucoma, and Alzheimer's disease.
In its latest funding round on October 17, 2022, Eyenuk secured a $26.00M Series A investment with backing from notable investors such as Kendall Capital Partners, KOFA Healthcare Investments, and others. This financial support underscores a growing confidence in Eyenuk’s groundbreaking applications in AI healthcare.
